Trial · NCT07887789
Visual Feedback-Assisted Sensorimotor Training in Chronic Nonspecific Low Back Pain
NCT07887789, Not applicable, Not yet recruiting, Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Visual Feedback-Assisted Sensorimotor Training in Chronic Nonspecific Low Back Pain. Trials, record NCT07887789. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07887789
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Visual Feedback-Assisted Sensorimotor Training in Chronic Nonspecific Low Back Pain
- NCT number
- NCT07887789
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
- Conditions
- Chronic Low Back Pain
- Interventions
- Visual Feedback-Assisted Sensorimotor Training, Conventional Exercise Training
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Pain Intensity (Numeric Rating Scale) | Baseline, Week 4 (post-intervention), and Week 8 (1-month follow-up) | Pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes in NRS scores from baseline to post-intervention and follow-up will be evaluated. |
| Primary | Change in Functional Disability (Roland-Morris Disability Questionnaire) | Baseline, Week 4 (post-intervention), and Week 8 (1-month follow-up) | Functional disability related to low back pain will be assessed using the Roland-Morris Disability Questionnaire (RMDQ). The total score ranges from 0 to 24, with higher scores indicating greater disability. Changes in RMDQ scores from baseline to post-intervention and follow-up will be evaluated. |
| Secondary | Change in Lumbar Two-Point Discrimination Threshold | Baseline, Week 4 (post-intervention), and Week 8 (1-month follow-up) | Lumbar tactile spatial acuity will be assessed using a two-point discrimination test with a caliper. The minimum distance at which participants can reliably distinguish two simultaneous touch points will be recorded in millimeters (mm). Lower thresholds indicate better tactile discrimination. Changes from baseline to post-intervention and follow-up will be evaluated. |
| Secondary | Change in Lumbopelvic Motor Control (Luomajoki Movement Control Tests) | Baseline, Week 4 (post-intervention), and Week 8 (1-month follow-up) | Lumbopelvic motor control will be assessed using the Luomajoki Movement Control Tests. The test battery consists of six movement control tests evaluating the ability to maintain appropriate lumbar spine control during functional movements. Each test is scored as 0 (correct performance) or 1 (incorrect performance), resulting in a total score ranging from 0 to 6. Higher scores indicate greater movement control impairment. Changes in total scores from baseline to post-intervention and follow-up will be evaluated. |
| Secondary | Change in Kinesiophobia (Tampa Scale of Kinesiophobia) | Baseline, Week 4 (post-intervention), and Week 8 (1-month follow-up) | Kinesiophobia will be assessed using the 17-item Tampa Scale of Kinesiophobia (TSK-17). Each item is rated on a 4-point Likert scale. The total score ranges from 17 to 68, with higher scores indicating greater fear of movement and reinjury. Changes in total TSK scores from baseline to post-intervention and follow-up will be evaluated. |
| Secondary | Change in Pain Catastrophizing (Pain Catastrophizing Scale) | Baseline, Week 4 (post-intervention), and Week 8 (1-month follow-up) | Pain catastrophizing will be assessed using the Pain Catastrophizing Scale (PCS), a 13-item self-report questionnaire evaluating rumination, magnification, and helplessness related to pain. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 52. Higher scores indicate greater pain catastrophizing. Changes in total PCS scores from baseline to post-intervention and follow-up will be evaluated. |
| Secondary | Change in Physical Health-Related Quality of Life (SF-12 Physical Component Summary) | Baseline, Week 4 (post-intervention), and Week 8 (1-month follow-up) | Health-related quality of life will be assessed using the 12-Item Short Form Health Survey (SF-12). The questionnaire provides two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Higher scores indicate better physical and mental health, respectively. Changes from baseline will be evaluated at post-intervention and follow-up. |
| Secondary | Change in Disability (WHODAS 2.0 - 12-item) | Baseline, Week 4 (post-intervention), and Week 8 (1-month follow-up) | Disability will be assessed using the 12-item World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). Each item is scored from 0 (no difficulty) to 4 (extreme difficulty or inability to perform), yielding a total score ranging from 0 to 48 using simple summation. Higher scores indicate greater disability. Changes from baseline will be assessed. |
| Secondary | Change in Mental Health-Related Quality of Life (SF-12 Mental Component Summary) | Baseline, Week 4 (post-intervention), and Week 8 (1-month follow-up) | Mental health-related quality of life will be assessed using the Mental Component Summary (MCS) score of the 12-Item Short Form Health Survey (SF-12). Higher scores indicate better mental health-related quality of life. Changes in MCS scores from baseline to post-intervention and follow-up will be evaluated. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07887789
GET https://conductscience.org/api/trials/v1/NCT07887789/registered